ClinicalTrials.gg
CompletedNCT02229955HL_TSPR_302Updated Sep 3, 2014

Study of Tisporin Eye Drops Group and Restasis Eye Drops Group After Treatment, Each Treatment Group Comparisons for Evaluation of Efficacy and Safety in Moderate to Severe Dry Eye Disease

A Phase 3 interventional study of Cyclosporine ophthalmic solution in Dry Eye Syndromes, sponsored by Hanlim Pharm. Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2014-09-03.

Sponsored by Hanlim Pharm. Co., Ltd. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing cyclosporine in Dry Eye Syndromes — 5 open to participants now, 5 under way, none of them phase 3. Cyclosporine · Dry Eye Syndromes.

Enrollment
14th of 41
86 · median 51
Started
2013
with 2 others
Phase 3
7 of 45
none open now
Registered
17th of 45
by date
Lead sponsor
2 of 45
Hanlim Pharm. Co., Ltd.

Among the 45 studies testing cyclosporine in Dry Eye Syndromes, this one is the 14th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2013, is one of 7 in phase 3, and was the 17th registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

5 of the 45 studies testing cyclosporine in Dry Eye Syndromes are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About cyclosporine

Cyclosporine: first FDA approval 1983 (SANDIMMUNE), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 45 studies testing cyclosporine in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The purpose of this clinical Study is Tisporin Eye Drops 0.05%(Cyclosporine ophthalmic solution) group and Restasis Eye Drops 0.05%(Cyclosporine ophthalmic suspension) group 12 weeks after treatment, each treatment group comparisons for evaluation of efficacy and safety in Moderate to Severe Dry Eye Disease.

  • Corneal staining test, Ocular surface disease index (OSDI), Tear break up time (TBUT), Non-anesthetic Schirmer test
03

Conditions studied

  • Dry Eye Syndromes

Browse trials for

Keywords

  • Dry Eye Syndromes
04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

[Patients with moderate-to-severe ocular dry eye]

  1. The One eye of corneal fluorescein staining score of 2 or higher (Oxford grading)
  2. Non-anesthetic Schirmer test value ≤ 10mm/5min patients at least one eye score (Non-anesthetic Schirmer test value = 0/5min, nasal stimulation in the same eye, Schirmer test value ≥ 3mm/5min)
  3. Tear break-up time is 10 seconds or less
  4. Screening both eyes, the corrected visual acuity is 0.2 or more
  5. Despite conventional treatment, the symptoms of dry eye signs (Artificial tear eye drops, sympathetic nervous system stimulant agent, parasympathetic nerve stimulant, etc.)

Exclusion criteria

Exclusion Criteria:

  1. Screening visits in the previous 3 months (12 weeks) who participated in the clinical trials of cyclosporine eye drops, or if you used a cyclosporin ophthalmic solutions.
  2. The patients with systemic or ocular disorders affected the test results (ocular surgery, trauma, or disease)

    1. Abnormal eyelid function : Disoders of the eyelids or eyelashes
    2. Ocular allergies or currently under the treatment of allergic diseases of the eye (topical ocular mast cell stabilizer, antihistamine use, etc.)
    3. Cicatricial keratoconjunctivitis caused by herpetic keratopathy, conjunctival scarring (alkali damage, Steven-Johnson syndrome, cicatricial pemphigoid), pterygium, pinguecula, lack of congenital lacrimal, neurogenic keratitis, keratoconus, corneal transplantation
  3. current or recent patients used dry eye syndrome medications (topical or systemic) that may affect the status
  4. The use in clinical trials of drug reactions in patients
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    T-sporin eye drop

    Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes

    Drug: Cyclosporine ophthalmic solution

  • Active comparator
    Restasis eye drop

    Cyclosporine 0.05% : 1 drop twice a day for 12 weeks to both eyes

    Drug: Cyclosporine ophthalmic solution

Interventions

06

What researchers measure

Primary outcomes

  1. Corneal staining test

    Time frame: 12 weeks

Secondary outcomes

  1. Corneal staining test

    Time frame: 4, 8 weeks

  2. Ocular surface disease index (OSDI)

    Time frame: 4, 8, 12 weeks

  3. Tear break up time (TBUT)

    Time frame: 4, 8, 12 weeks

  4. Non-anesthetic Schirmer test

    Time frame: 4, 8, 12 weeks

  5. Conjunctival staining

    Time frame: 4, 8, 12 weeks

07

Study locations

1 site
  • The catholic university of Korea seoul st. Mary's hospital
    Seoul, Seocho-Ku 137-701, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2013, a primary completion of Apr 2014 and a completion of Jul 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 29, 2014
First posted
Sep 3, 2014
Start
Dec 2013
Primary completionActual
Apr 2014
CompletionActual
Jul 2014
Last update
Sep 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02229955
Responsible party
Sponsor
First posted
Sep 3, 2014
Start date
Dec 2013
Primary completion
Apr 2014
Completion
Jul 2014
Last update
Sep 3, 2014

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cyclosporine

Start the discussion